Document:

EXHIBIT
10.99

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is
made and entered into effective as of February 5, 2007, (the “Effective Date”)
by and between Advanced Cell Technology, Inc., a Delaware corporation with offices at
381 Plantation Street, Worcester, Massachusetts 01605 (the “Company”) and Pedro Huertas, M.D.,
Ph.D. (“Employee”).

1.             TERM OF AGREEMENT

The term of this Agreement shall commence on the
Effective Date and continue until the termination of Employee’s employment by the
Company pursuant to the terms of this Agreement (such period of employment, the
“Employment Period”).

2.             DUTIES AND PERFORMANCE

(a)           During the Employment Period,
Employee shall be employed by the Company on a full-time basis as its Chief
Development Officer and shall have such authority and shall perform such duties
consistent with his position as may be reasonably assigned to him, including
but not limited to Preclinical, Medical, Clinical, Regulatory and Quality
Assurance/Quality Control and shall report to the Chief Executive Officer of
the Company.  Employee shall use all
reasonable efforts to further the interests of the Company and, except as
approved by the Chief Executive Officer, shall devote all of his business time
and attention to his duties hereunder.

(b)            
Except with the approval of the Chief Executive Officer, Employee,
during the Employment Period or any renewal thereof, will not (i) accept any
other employment, or (ii) engage, directly or indirectly, in any other
business activity (whether or not pursued for pecuniary advantage) that is or
may be competitive with, or that might place him in a competing position to,
that of the Company or any of its Affiliates (as defined in Section 7 hereof);
provided, however, the Company acknowledges and agrees to Employees’
participation in advisory boards and consulting arrangements with third parties
and a faculty position at Massachusetts General Hospital so long as such
activities do not affect or interfere with Employee’s performance under this
Agreement.

(c)           Employee shall be entitled to be
reimbursed in accordance with the policies of the Company, as adopted and
amended from time to time, for all reasonable standard and necessary expenses
incurred by him in connection with the performance of his duties hereunder; provided
that Employee shall, as a condition of such reimbursement, submit verification
of the nature and amount of such expenses in accordance with the reimbursement
policies from time to time adopted by the Company.

3.             BASE SALARY AND OTHER
COMPENSATION

(a)           Base Salary.  The Company shall pay to Employee a base
salary at the rate of Two Hundred and Ninety Thousand Dollars ($290,000) per
annum (the “Base Salary”) during the Employment Period, payable as per
the normal payroll periods and pay practices of the Company (e.g., standard
employee deductions such as income tax withholdings, social security,

1

 

etc.).  The Base Salary shall be reviewed in
connection with Employee’s annual performance review and may be increased upon
the recommendation by Chief Executive Officer to and in the sole discretion of
the Board of Directors or the Compensation Committee of the Board of Directors
(the “Compensation Committee”).

(b)           Equity Compensation.  Employee shall be entitled to receive a grant
of an option to purchase One Million Three Hundred Thousand (1,300,000) shares
of Company common stock (the “Option Grant”) pursuant to the Company’s 2005
Stock Incentive Plan (the “2005 Plan”). 
Except as set forth in Section 3(d) below, the Option Grant shall vest
over a 48 month period as follows: 1/48th of the shares will vest
each month during the term of this Agreement. 
The shares shall be priced in accordance with the existing terms and
conditions of the 2005 Plan.  In the
event of a Change of Control (as defined in the 2005 Plan) of the Company after
the Effective Date, Employee shall immediately vest in fifty percent (50%) of
the unvested shares under the Option Grant. 
Employee shall enter into and deliver all agreements as required under
the 2005 Plan.  Employee shall be
entitled to participate in any discounted employee stock purchase plan in the
event such plan is established by the Company in the future.  In the event the Board of Directors and
shareholders of the Company approve additional shares for the 2005 Plan, ,
Employee shall be included in any additional grants of equity compensation to
the members of the executive management of the Company as determined in the
sole discretion of the Board of Directors.

 (c)          Bonus
Compensation.  In addition to the
Base Salary and the equity compensation described in this Agreement, Employee
shall receive an annual performance bonus determined by the Chief Executive
Officer and the Board of Directors of the Company.

(d)           Additional Incentive.  As a signing bonus, Employee shall
immediately vest in 10% of the Option Grant (i.e. 130,000 shares).

(e)           Automobile Allowance.  Employee shall be entitled to a monthly
automobile allowance in the amount of One Thousand Dollars ($1,000) per month.

 (f)           CME.  The Company acknowledges that to maintain his
standing in the medical and scientific community, Employee belongs to various
professional societies, participates in professional organizations and
occasionally fulfills continuing medical education (CME) credits.  The Company will reimburse Employee for all
reasonable costs of membership, journal and CME activities.

 (g)          Company
Equipment.  The Company will pay for
purchase and maintenance of communication equipment, including but not limited
to computer and telephone, necessary for the performance of Employee’s duties
outside Company headquarters in Worcester, Massachusetts, USA.

4.             BENEFITS

Employee shall be entitled to participate, to the
extent Employee may be eligible, in any group medical and hospitalization,
profit sharing, retirement, life insurance or other employee benefit plan
maintained by the Company and its subsidiaries for their full time employees

2

 

(collectively, “Benefits”), pursuant to the
terms of such plan(s).  The Benefits made
available to Employee shall be no less favorable than the benefits made
available to other similarly situated senior executives of the Company.  Employee shall be entitled to three (3) weeks
of paid vacation per year, which vacation shall accrue and be taken in
accordance with the Company’s policies in effect from time to time.

5.             TERMINATION OF EMPLOYMENT

(a)           Termination.  Employee’s employment hereunder will be
terminated, if any of the following circumstances occurs:

(i)            Termination for Cause.  The Company may terminate Employee’s
employment hereunder for Cause by delivery of a written notice to Employee
concerning the same.  “Cause”
shall mean any of the following: (A) a material breach by Employee of the
provisions of this Agreement, or Employee’s Confidential  Information, Invention and Non-Competition
Agreement with the Company; (B) Employee’s future conviction of, or plea, of
guilt or nolo contendere to, any felony or to any
crime or offense (whether or not for personal gain) or involving acts of theft,
fraud, embezzlement or moral turpitude; (C) gross negligence or intentional or
willful misconduct in the performance of Employee’s duties, failure to
faithfully and diligently perform the duties of Employee’s employment or his
habitual neglect thereof; (D) intentional and repeated failure to materially
follow or comply with the lawful directives of the Chief Executive Officer or
with lawful policies, standards or regulations of the Company; and (E)
fraudulent conduct or willful unethical conduct by Employee that materially
discredits the Company or is materially detrimental to the reputation,
character or standing of the Company.  In
the case of the foregoing clauses, if any such breach, misconduct or failure is
capable of being cured, as determined in the Board of Directors’ reasonable
judgment, “Cause” shall mean any failure to cure such breach, misconduct
or failure within a reasonable period (not to exceed thirty (30) calendar days,
which period may be extended by the Board of Directors if Employee is
diligently pursuing a cure) after Employee has been informed, in writing
thereof.

(ii)           Termination without Cause.  Notwithstanding anything to the contrary
contained herein, including in Section 1 of this Agreement, Employee’s
employment with the Company may be terminated by the Company at any time, for
any reason, without Cause upon providing thirty (30) days prior written notice
to Employee.

(iii)          Disability.  Employee’s employment hereunder shall
terminate if, because of a mental or physical disability or infirmity, Employee
is unable to perform the essential functions of his duties, taking into account
any reasonable accommodations that do not impose an undue burden on the
Company, for a consecutive period of one hundred twenty (120) days or a
non-consecutive period of one hundred twenty (120) days during any twelve (12)
month period, or such other greater period as may be required by applicable
employment laws, taking

3

 

into consideration
any sick, vacation or other leave time available under the Company’s policies
in effect at such time.

(iv)          Death.  Employee’s employment hereunder shall
terminate upon the death of Employee.

(v)           Resignation.  Employee’s employment hereunder shall
terminate upon the voluntary resignation of Employee and Employee shall be free
to resign for any or no reason upon two weeks’ prior written notice to the
Company.

(b)           Compensation Upon Termination.

(i)            Termination for Cause.  If Employee’s employment is terminated for
Cause pursuant to Section 5(a)(i) hereof, then the Company shall pay Employee
(A) the Base Salary through the Date of Termination and (B) accrued but
unpaid benefits for Employee (accrued but unpaid expenses, and accrued but
unused vacation pay) as of the Date of Termination (collectively the items set
forth in this clause (B) being referred to herein as the “Accrued Benefits”).  Employee and his dependents shall also be
entitled to any continuation of coverage rights required by COBRA (as
hereinafter defined).

(ii)           Termination by the Company.  If the Company terminates Employee’s
employment without Cause pursuant to Section 5(a)(ii) hereof, then (A) the
Company shall pay Employee: (1) the Base Salary through the Date of Termination
and (2) the Accrued Benefits, (B) a lump sum payment (less payroll deductions
and withholdings) equal to twelve (12) months Base Salary (in effect as of the
time of the Date of Termination), (C) Employee and his dependents shall be
entitled to any continuation of coverage rights required by COBRA, and the
Company shall continue to pay the same COBRA premiums of Employee and his
dependents for a period of twelve (12) months following the Date of Termination
that the Company had paid prior to termination, and (D) Employee shall
immediately vest upon the Date of Termination in one hundred percent (100%) of
all remaining unvested shares under the Option Grant.  The Company shall take all necessary steps to
ensure that any and all payments hereunder either comply with or are excluded
from Section 409A of the Internal Revenue Code of 1986, as amended.

(iii)          Disability or Death.  If Employee’s employment shall be terminated
pursuant to Section 5(a)(iii) or 5(a)(iv), then (A) the Company shall pay
Employee or his estate, as applicable, (1) the Base Salary through the Date of
Termination, (2) the Accrued Benefits, and (3) any other benefits payable on
behalf of Employee as shall be determined under the Company’s insurance and
other benefit plans and programs then in effect in accordance with the terms of
such programs.  In addition, the Company
shall keep in force existing Benefits covering Employee and his dependents for
a period of one (1) year from the Date of Termination on the basis in effect at
the Date of Termination of Employee’s employment, subject to the Company’s
right to amend, modify or terminate any

4

 

such plan.  Thereafter, Employee and his dependents shall
be entitled to any continuation of coverage rights required by COBRA.

(iv)          Resignation.  (A) If Employee voluntarily resigns his
position without Good Reason and voluntarily terminates his employment with the
Company or otherwise voluntarily quits as an employee of the Company without
Good Reason, then the Company shall pay Employee (1) the Base Salary through
the Date of Termination and (2) the Accrued Benefits.  Thereafter, Employee and his dependents shall
be entitled to any continuation of coverage rights required by COBRA.

(v)           Termination for Good Reason.  If Employee timely resigns his position with
Good Reason and terminates his employment with the Company or otherwise quits
as an employee of the Company with Good Reason, then (I) the Company shall pay
Employee (a) the Base Salary through the Date of Termination and (b) the
Accrued Benefits, (II) a lump sum payment (less payroll deductions and
withholdings) equal to twelve (12) months Base Salary (in effect as of the time
of the Date of Termination), (III) Employee and his dependents shall be
entitled to any continuation of coverage rights required by COBRA, and the
Company shall continue to pay the same COBRA premiums of Employee and his
dependents for a period of twelve (12) months following the Date of Termination
that the Company had paid prior to termination, and (IV) Employee shall
immediately vest upon the Date of Termination in one hundred percent (100%) of
remaining unvested shares under the Option Grant.  The Company shall take all necessary steps to
ensure that any and all payments hereunder either comply with or are excluded
from Section 409A of the Internal Revenue Code of 1986, as amended.

(vi) Termination Upon Change in Control. If a
Change in Control occurs and Employee resigns with Good Reason or is terminated
without Cause in anticipation of the Change of Control or within twelve (12)
months of such Change in Control, then Employee will be entitled to receive a
lump sum payment (less payroll deductions and withholdings) equal to twelve
(12) months of Base Salary (in effect as of the Date of Termination), 100%
vesting of all unvested Options, continuation of all benefits for twelve (12)
months, plus payment of bonuses expected during the twelve (12) months after
the Date of Termination. The Company shall take all necessary steps to ensure
that any and all payments hereunder either comply with or are excluded from
Section 409A of the Internal Revenue Code of 1986, as amended.

(c)           As used herein, “COBRA” shall
mean Section 4980B of the Internal Revenue Code of 1986, as amended, and
Sections 601 through 608 of the Employee Retirement Income Security Act of
1974, as amended, and any applicable state law establishing employer
requirements for continuation of group health care, life insurance or other
welfare plan benefits for the benefit of certain current and former employees
or dependents thereof.

5

 

(d)           “Date of Termination” shall
mean the last day of Employee’s employment by the Company.

(e)           “Good Reason” shall mean, in each
case without the consent of Employee, (i) a material reduction in Employee’s
Base Salary (unless such reduction is associated with a concurrent reduction of
salary of other similarly situated senior executives of the Company), or (ii) a
material reduction or diminution of Employee’s title, duties, responsibilities,
or authority below that of a Chief Development 
Officer in charge of Preclinical, Medical and Clinical Affairs,
Regulatory and Quality Assurance/Quality Control, or (iii) the Company’s
material breach of this Agreement; provided that the Company (A) first be given
reasonable written notification by Employee of such alleged events, activities
or omissions, and (B) a reasonable opportunity (of not less than thirty (30)
days) to cure such events, activities or omissions if capable of being cured,
or (iv) relocation of the Company, or its successor, more than fifty (50) miles
away from the Company’s current location at 381 Plantation Street, Worcester, Massachusetts 01605 USA.

(f)             “Change in Control” means
any of the following (i) any person or entity becomes the beneficial owner of
greater than fifty per cent (50%) of the then outstanding voting power of the
Company with corresponding designated control of the Board of Directors; (ii) a
merger or consolidation with another entity where the voting securities of the
Company that are outstanding immediately before the transaction constitute less
than a majority of the voting power of the voting securities of the company or
the surviving entity outstanding immediately after the transaction; or (iii)
the sales and disposition of all or substantially all of the company’s assets.
This provision will not apply a re-capitalization of the company where control
is maintained by the current Board of Directors or a strategic partnership
relationship where Board control is not altered.

(g)           Employee’s Obligations at
Termination.  Employee hereby
acknowledges and agrees that all Personal Property and equipment furnished to
or prepared by Employee in the course of or incident to his employment, belongs
to the Company and shall be promptly returned to the Company upon termination
of Employee’s employment hereunder.  “Personal
Property” includes, without limitation, all books, manuals, records,
reports, notes, contracts, lists, encoded media, and other documents or
materials, or copies thereof (including computer files), and all other
proprietary information relating to the business of the Company.  As of the Date of Termination, Employee will
not retain any written or other tangible material containing any proprietary
information of the Company.  Upon
termination of Employee’s employment hereunder for any reason, Employee shall
be deemed to have resigned from all offices and Board of Directors positions
and other directorships then held with the Company or any Affiliate (as defined
in Section 7).

(h)           The termination of the Employment
Period by the Company or Employee shall be without liability to the Company
except as specifically set forth in this Agreement.

6

 

(i)            Notwithstanding anything in this
Agreement to the contrary, Employee shall not be entitled to any accelerated
vesting or continuation of salary or benefits (including COBRA premiums)
payments following the Date of Termination, unless and until Employee shall
enter into the Company’s standard form of general release mutually acceptable
to the Company and Employee in favor of the Company and its affiliates and is
not revoked.

(j)            4999 / 409A

(i)            4999

In the event that it is determined that any payment or
benefit provided by the Company to or for the benefit of Employee, either under
this Agreement or otherwise, will be subject to the excise tax imposed by
section 4999 of the Internal Revenue Code or any successor provision (“Section
4999”), the Company will, prior to the date on which any amount of the excise
tax must be paid or withheld, make an additional lump-sum payment (the “4999
gross-up payment”) to Employee.  The 4999 gross-up payment will be
sufficient, after giving effect to all federal, state and other taxes and
charges (including interest and penalties, if any) with respect to the 4999
gross-up payment, to make Employee whole for all taxes (including withholding
taxes) and any associated interest and penalties, imposed under or as a result
of Section 4999.

Determinations under this section will be made by an
accounting firm chosen by the Company and Employee (the firm making the
determinations to be referred to as the “Firm”).  The determinations of
the Firm will be binding upon the Company and Employee except as the
determinations are established in resolution (including by settlement) of a
controversy with the Internal Revenue Service (“IRS”) to have been
incorrect.  All fees and expenses of the Firm will be paid by the Company.

If the IRS asserts a claim that, if successful, would
require the Company to make a 4999 gross-up payment or an additional 4999
gross-up payment, the Company and Employee will cooperate fully in resolving
the controversy with the IRS.  The Company will make or advance such 4999
gross-up payments as are necessary to prevent Employee from having to bear the
cost of payments made to the IRS in the course of, or as a result of, the
controversy. The Firm will determine the amount of such 4999 gross-up
payments or advances and will determine after final resolution of the
controversy whether any advances must be returned by Employee to the
Company.  The Company will bear all
expenses of the controversy and will gross Employee up for any additional taxes
that may be imposed upon Employee as a result of its payment of such expenses.

(ii) 409A

To the extent any payment hereunder shall be required
to be delayed until six months following separation from service to comply with
Section 409A it shall be so delayed (but not more than is required to comply
with such rules).  The parties hereto acknowledge that in addition to any
delay required under Section 409A, it may be desirable, in view of regulations
or other guidance issued by the IRS under Section 409A

7

 

of the Code, to amend provisions of the Agreement to avoid taxes and/or
penalties under Section 409A of the Code and that the Company will not
unreasonably withhold its consent to any such amendments which in its
determination are (i) feasible and necessary to avoid adverse tax consequences
under Section 409A of the Code for Employee, and (ii) not adverse to the
interests of the Company.

In the event that it is determined that any payment or
benefit provided by the Company to or for the benefit of Employee, either under
this Agreement or otherwise, will be subject to taxes and/or penalties and/or
interest imposed by section 409A of the Internal Revenue Code or any successor
provision (“Section 409A”), the Company will, prior to the date on which any
amount of such taxes and/or penalties and/or interest must be paid or withheld,
pay to Employee an additional amount (the “409A gross-up payment”) that after
reduction for all taxes (including but not limited to the Section 409A taxes
and/or penalties and/or interest with respect to such 409A gross-up payment)
equals any Section 409A taxes and/or penalties and/or interest such that
Employee is made whole; provided,
that to the extent any 409A gross-up payment would be considered “deferred compensation”
for purposes of Section 409A of the Code, the manner and time of payment, and
the provisions of this paragraph, shall be adjusted to the extent necessary to
comply with, or be excluded from, the requirements of Section 409A with respect
to such payment so that the 409A gross up payment does not give rise to
additional 409A taxes and/or penalties and/or interest.

Determinations under this section will be made by an
accounting firm chosen by the Company and Employee (the firm making the
determinations to be referred to as the “Firm”).  The determinations of
the Firm will be binding upon the Company and Employee except as the
determinations are established in resolution (including by settlement) of a
controversy with the Internal Revenue Service (“IRS”) to have been
incorrect.  All fees and expenses of the Firm will be paid by the Company.

If the IRS asserts a claim that, if successful, would
require the Company to make a 409A gross-up payment or an additional 409A
gross-up payment, the Company and Employee will cooperate fully in resolving
the controversy with the IRS.  The Company will make or advance such 409A
gross-up payments as are necessary to prevent Employee from having to bear the
cost of payments made to the IRS in the course of, or as a result of, the
controversy. The Firm will determine the amount of such 409A gross-up
payments or advances and will determine after final resolution of the
controversy whether any advances must be returned by Employee to the Company.  The Company will bear all expenses of the
controversy and will gross Employee up for any additional taxes that may be
imposed upon Employee as a result of its payment of such expenses.

6.             LIABILITY AND INDEMNIFICATION

The Company shall hold
during the Employment Period and for at least five (5) years thereafter
sufficient insurance to defend and indemnify Employee for any claims against
him during the lawful discharge of his duties, to the extent that the Employee

8

 

comports to company
policy and appropriate law, to the Company and shall hold him and his estate
harmless against such claims.

7.             CONFIDENTIALITY

(a)           Confidentiality.  Employee agrees and acknowledges that all
right, title and interest in and to the Employee Confidential Information,
Invention and Non-Competition Agreement shall be owned by and remain vested in
the Company.  Employee shall enter into
and deliver the Company’s standard form of Proprietary Information and
Invention Agreement.  Except as consented
to by the Company and as and to the extent required by, law, Employee hereby
agrees that Employee will not, directly or indirectly, disclose or make
available to any person, firm, corporation, association or other entity for any
reason or purpose whatsoever, any Confidential Information.  Employee agrees that, upon termination of his
employment hereunder, all Confidential Information in his possession that is in
written or other tangible form (together with all copies or duplicates thereof,
including computer files) shall be returned to the Company and shall not be
retained by Employee or furnished to any third party, in any form except as
provided herein.  As used in this
Agreement, the term “Confidential Information” means information
disclosed to Employee or known by Employee as a consequence of or through his
relationship with the Company, about the customers, employees, business
methods, public relations methods, organization, procedures or finances,
including, without limitation, information of or relating to supplier and
customer lists of the Company and its Affiliates, patents, copyrights,
know-how, trade secrets, research, product plans, prices and costs, markets,
developments, test data, forecasts, budgets and other confidential or
proprietary business, technical, personnel or financial information, whether or
not Employee’s work product, in written, graphic, oral or other tangible or
intangible forms, including but not limited to specifications, samples,
records, data, computer programs, services, suppliers, pricing policies,
drawings, diagrams, models, customer names, ID’s or email addresses and
relationships, business or marketing plans, studies, analyses, projections and
reports, communications by or to attorneys (including attorney-client
privileged communications), memos and other materials prepared by attorneys or
under their direction (including attorney work product), hardware/software
systems and processes and other valuable confidential business information, in
each case that qualifies as a trade secret and has independent economic value; provided,
however, that “Confidential Information” shall not include any such
information that Employee can show (i) was publicly known at the time of
disclosure to Employee, (ii) becomes publicly known or available thereafter
other than by any means in violation of this Agreement or any other duty owed
to the Company by any person or entity, which duty is known to Employee or
(iii) is lawfully disclosed to Employee by a third party owing no duty of
confidentiality to the Company.  Subject
to the foregoing, any information that is not readily available to the public
shall be considered to be a trade secret and confidential and proprietary, even
if it is not specifically marked as such, unless the Company advises Employee
otherwise in writing.  The parties hereto
stipulate and agree that the foregoing matters are important, material and
confidential proprietary information and trade secrets that affect the
successful

9

 

conduct of the business
of the Company (and any successor or assignee of the Company).  Employee will keep the Confidential
Information in strictest confidence and trust. 
Employee also acknowledges and agrees that the Company’s products are
marketed anywhere in the world, the market in which the Company competes is
worldwide and, therefore, the protection afforded the Company pursuant to the
provisions of this Section 6 shall be worldwide.

(b)           Injunctive Relief and Enforcement.  In the event of breach by Employee of the
terms of this Section 6, the Company shall be entitled to institute legal
proceedings to obtain damages for any such breach, or to enforce the specific
performance of this Agreement by Employee and to enjoin Employee from any
further violation of this Section 6, and to exercise such remedies cumulatively
or in conjunction with all other rights and remedies provided by law.  Employee acknowledges, however, that the
remedies at law for any breach by him of the provisions of this Section 6 may
be inadequate.  In addition, in the event
that any of the agreements in this Section 6 shall be determined by any court
of competent jurisdiction to be unenforceable by reason of extending for too
great a period of time or over too great a geographical area or by reason of
being too extensive in any other respect, it shall be interpreted to extend
over the maximum period of time for which it may be enforceable and to the
maximum extent in all other respects as to which it may be enforceable, and
enforced as so interpreted, all as determined by such court in such action.

8.             AFFILIATES

As used in this Agreement, “Affiliates” shall
mean any partnership, joint venture, limited liability company or corporation
that, directly or indirectly through one or more intermediaries Controls, or is
Controlled by, or is under common Control with, the Company.  The term “Control” includes, without
limitation, the possession, directly or indirectly, of the power to direct the
management and policies of a corporation, partnership, joint venture or limited
liability company, whether through the ownership of voting securities, by
contract or otherwise.

9.             NOTICE

All notices, requests, demands and other
communications which are required or may be given under this Agreement shall be
in writing and shall be delivered personally to the party intended to receive
such notice, or sent by a national overnight delivery or courier company or by
U.S. registered or certified mail, postage prepaid, return receipt requested,
and sent to:

	
  If to Employee:

  	
   

  	
  Pedro Huertas, M.D., Ph.D.

  
	
   

  	
   

  	
  283 Simon Willard Road

  
	
   

  	
   

  	
  Concord, MA 01742-1625

  
	
   

  	
   

  	
  Tel: 978-394-5700

  
	
   

  	
   

  	
   

  

 

10

 

 

	
  If to the Company:

  	
   

  	
  Advanced Cell Technology, Inc.

  
	
   

  	
   

  	
  1201 Harbor Bay Parkway, Suite 120

  
	
   

  	
   

  	
  Alameda, CA 94502

  
	
   

  	
   

  	
  Tel: 510.748.9400

  
	
   

  	
   

  	
  Fax: 510.748. 9450

  

 

or to such other place and with such other copies as
either party may designate as to itself by written notice to the others.  Any such notices shall be deemed delivered
upon delivery or refusal to accept delivery as indicated in writing by the
party attempting to make personal service, on the U.S. Postal Service return
receipt, or by similar written advice from the overnight delivery company; provided,
however, that if any such notice shall also be sent by electronic
transmission device, such as telex, telecopy, fax machine or computer to the
fax number set forth above, such notice shall be deemed delivered at the time
and on the date of machine transmittal (except if sent after 5:00 p.m.
recipient’s time, in which case the notice shall be deemed delivered at 9:00
a.m. on the next business day) if the sending party receives a written send
verification on its machine and sends a duplicate notice on the same day or the
next business day by personal service, registered or certified U.S. mail, or
overnight delivery in the manner described above.

10.          DIVISIBILITY OF AGREEMENT

In the event that any term, condition or provision of
this Agreement is for any reason rendered void, all remaining terms, conditions
and provisions shall remain and continue as valid and enforceable obligations
of the parties hereto.

11.          CHOICE OF LAW

This Agreement shall be construed, interpreted and the
rights of the parties determined in accordance with the laws of the State of
California (without reference to the choice of law provisions of such State’s
law).

12.          ARBITRATION

Notwithstanding anything herein to the contrary, in
the event that there shall be a dispute among the parties arising out of or
relating to this Agreement or the breach thereof, the parties agree that such
dispute shall be resolved by final and binding arbitration in Boston,
Massachusetts administered by the American Arbitration Association (“AAA”),
in accordance with the AAA’s National Rules for the Resolution of Employment
Disputes then in effect.  Depositions may
be taken and other discovery may be obtained during such arbitration
proceedings to the same extent as authorized in civil judicial
proceedings.  Any award issued as a
result of such arbitration shall be final and binding between the parties
thereto, and shall be enforceable by any court having jurisdiction over the party
against whom enforcement is sought.  Notwithstanding
anything to the contrary contained in this Section 12, nothing shall prevent
the parties hereto from seeking provisional remedies or injunctive relief in a
court of law.

13.          SERVICE OF PROCESS; CONSENT TO JURISDICTION

(a)           Service of Process.  Each of the parties hereto irrevocably
consents to the service of any process or pleading by any method permitted
under California law.

11

 

(b)           Consent to Jurisdiction.  Each party hereto irrevocably and unconditionally:
(i) agrees that any suit, action or other legal proceeding arising out of this
Agreement may be brought in the United States District Court for the Eastern
District of Massachusetts or, if such court is precluded by law from accepting
jurisdiction, in any court of general jurisdiction in the Suffolk County of
Massachusetts; (ii) consents to the jurisdiction of any such court in any such
suit, action or proceeding; and (iii) waives any objection which such party may
have to the laying of venue of any such suit, action or proceeding in any such
court.

14.          COMPLETE AGREEMENT

This Agreement contains the entire understanding of
the parties with respect to the employment of Employee and supersedes all prior
arrangements or understandings with respect thereto and all oral or written
employment agreements or arrangements between the Company (and any of its
subsidiaries) and Employee; provided that nothing herein shall supersede or
terminate or modify the provisions of the Employee Confidential Information,
Invention and Non-Competition Agreement or any agreements related to the 2005
Plan with the Company, and the provisions hereof shall be additive to the
provisions of those agreements.  This
Agreement may not be altered or amended except by writing, duly executed by the
party against whom such alteration or amendment is sought to be enforced.

15.          ASSIGNMENT

This Agreement is personal and non-assignable by
Employee.  It shall inure to the benefit
of any corporation or other entity with which the Company shall merge or
consolidate or to which the Company shall lease or sell all or substantially
all of its assets and may be assigned by the Company to any Affiliate of the
Company or to any corporation or entity with which such Affiliate shall merge
or consolidate or which shall lease or acquire all or substantially all of the
assets of such Affiliate; provided that as a condition to such sale of
assets or merger, the purchaser or surviving company, as the case may be, shall
have assumed all of the obligations and duties of the Company under this
Agreement and the Company shall not be released of its obligations under this
Agreement; provided  further that Employee shall have the right to
raise any defense against, or set off against any claim or demand of, any assignee
of the Company that Employee could have raised to or set off against the
Company in the absence of such assignment.

16.          COUNTERPARTS

This Agreement may be executed and delivered in
counterparts (which may be by fax or photocopy), each of which shall be an
original and all of which together shall constitute one and the same
instrument.

17.          EMPLOYEE’S ACKNOWLEDGMENT

Employee acknowledges (a) that he has consulted with
or has had the opportunity to consult with independent counsel of his own
choice concerning this Agreement and has been advised to do so by the Company,
and (b) that he has read and understands the Agreement, is fully aware of its
legal effect, and has entered into it freely based on his own judgment.

12

 

[Signature Page
Follows]

13

 

IN WITNESS WHEREOF, each
of the parties hereto has executed this Agreement as of the day and year first
above written.

	
  

  	
   

  	
  “EMPLOYEE”

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  /s/ PEDRO HUERTAS

  
	
   

  	
   

  	
  Pedro Huertas, M.D., Ph.D.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  “COMPANY”

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  ADVANCED CELL TECHNOLOGY, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  /s/ WILLIAM M. CALDWELL, IV

  
	
   

  	
   

  	
  By: William M. Caldwell, IV

  
	
   

  	
   

  	
  Title: Chairman and Chief Executive Officer

  

 

 

 

 

 

 

 

 

 

Signature Page to
Employment AgreementEXHIBIT 10.100

RESEARCH
SERVICES AGREEMENT

BETWEEN

OHSU
AND ADVANCED CELL TECHNOLOGY, INC.

This
Agreement (“Agreement”), dated and
effective as of  February 5, 2007 (the “Effective Date”), is between the Oregon
Health & Science University, having offices at 2525 SW 1st Ave,
Suite 120 Portland, Oregon 97201-4753 (“UNIVERSITY”), and Advanced Cell
Technology, Inc. having offices at 1201 Bay Harbor Parkway, Alameda, CA  94052 (“COMPANY”).

1.                                      BACKGROUND

1.1                                 COMPANY desires research services in accordance with the scope of work
outlined per Attachment A, and

1.2                                 The performance of such research is consistent, compatible and
beneficial to the academic role and mission of UNIVERSITY as an institution of
higher education, and, in consideration of the mutual promises and covenants
contained herein, the parties hereto agree as follows:

2.                                      SCOPE OF WORK

2.1                                 UNIVERSITY
agrees to use all reasonable best efforts to perform for COMPANY the research
activities described in Attachment A, hereinafter the SCOPE OF WORK, under the
direction and supervision of Raymond Lund, PRINCIPAL INVESTIGATOR.

3.                                      TERM

3.1                                 This Agreement
shall become effective upon being fully signed by both parties to this
Agreement, and shall be shall be effective for a period of  24 (twenty-four) months   unless mutually agreed upon in writing between
the parties.  Cost incurred prior to the
effective date which would have been allowed had the agreement been fully
executed as of February 1, 2007 shall be allowed.

4.                                      COMPENSATION

4.1                                 COMPANY agrees
to reimburse UNIVERSITY for services performed under this Agreement in the
amount of $345,328 in accordance with the budget itemized in Attachment B, 50%
of the amount will be payable within thirty (30) days from execution of this
Agreement and the remaining 50% will be payable within one hundred and twenty
(120) days from the execution of this Agreement.  Checks to UNIVERSITY shall be made payable to
OREGON HEALTH & SCIENCE UNIVERSITY and mailed to:

OREGON
HEALTH & SCIENCE UNIVERSITY

Sponsored
Projects Administration

2525
SW 1st Avenue, Suite 220

Portland,
OR 97201

Tax
ID No.: 93-1176109

5.                                      REPORTING REQUIREMENTS

5.1                                 UNIVERSITY will
provide reports on the progress of the research as outlined or required in the

 

SCOPE OF WORK. All original raw data, records and reports shall be the
property of UNIVERSITY, and UNIVERSITY shall retain all original data, records,
and reports as per Clause 10.0 of the SCOPE OF WORK. Said written reports will
be written as per Clause 9.0 of the SCOPE OF WORK. COMPANY shall be entitled to
make use of the data, records, and reports for any purpose.

6.                                      CONFIDENTIALITY AND PUBLICATION

6.1                                 UNIVERSITY
and PRINCIPAL INVESTIGATOR agree to keep confidential any COMPANY confidential
and proprietary information supplied to it in writing by COMPANY and marked
CONFIDENTIAL during the course of research performed by UNIVERSITY
(Confidential Information).  This
obligation extends for a period of five (5) years after the term of this
Agreement.  Such Confidential Information
will not be included in any published material without prior approval by
COMPANY.  The obligations of this Section
shall not apply to:

(a)          information which is or becomes known publicly through no fault of the
UNIVERSITY or PRINCIPAL INVESTIGATOR;

(b)         information learned by UNIVERSITY or PRINCIPAL INVESTIGATOR through a third
party entitled to disclose it;

(c)          information developed by UNIVERSITY or PRINCIPAL INVESTIGATOR
independently  of information obtained
from COMPANY as shown by written records;

(d)         information already known to UNIVERSITY or PRINCIPAL INVESTIGATOR before
COMPANY’s disclosure as shown by witnessed prior written records; or

(e)          information required to be disclosed to by law, including the Oregon Public
Records Law, to comply with government regulations, subpoenas or court orders
provided COMPANY receives adequate notice of such demand and provided
UNIVERSITY or PRINCIPAL INVESTIGATOR makes any such disclosure under an order
protecting the confidential nature of proprietary information.

6.2                                 UNIVERSITY
agrees to provide any proposed publication to COMPANY thirty (30) days prior to
submission, for confidential review for the inclusion of COMPANY Confidential
Information, and to determine whether patentable inventions of discoveries are
disclosed therein.  COMPANY has the right
to edit or remove COMPANY Confidential Information, prior to submission for
publication.  Should the documents
contain any patentable information, at COMPANY’s request UNIVERSITY shall
withhold submission and/or publication for an additional sixty (60) days to
allow U.S. patent filings.  In addition,
in the event that the document includes data, information or material generated
by COMPANY’s scientists, and professional standards for authorship would be
consistent with including COMPANY’s scientists as co-authors of the document,
the names of COMPANY’s scientists will be included as co-authors.

7.                                      EQUIPMENT

7.1                                 All
equipment purchased under the terms of this agreement becomes the property of
UNIVERSITY unless otherwise specified herein.

8.                                      INDEMNIFICATION

8.1                                 Each party
hereto agrees to be responsible and assume liability for its own wrongful or
negligent acts or omissions, or those of its officers, agents or employees to
the full extent required by law, including the Oregon Tort Claims Act, ORS
Sections 30.260 through 30.300.

 

9.                                      COMPLIANCE WITH LAWS

9.1                                 UNIVERSITY
and PRINCIPAL INVESTIGATOR agree to comply with all applicable federal, state
and local laws, codes, regulations, rules and orders.

10.                               ASSIGNMENT

10.1                           Neither party shall assign or transfer any interest in this Agreement, nor
assign any claims for money due or to become due during this Agreement, without
the prior written approval of the other party.

11.                               PUBLICATION BY COMPANY

11.1                           COMPANY will not include the name of UNIVERSITY in any advertising, sales,
promotion, or other publicity matter without prior written approval of
UNIVERSITY.

12.                               TERMINATION

12.1                           Either party may terminate this Agreement at any time if:

(a)          The other party materially
breaches the terms of this Agreement, provided that the non-breaching party
shall have given the breaching party written notice of such breach and the
breaching party shall have failed to cure the same within thirty (30) days
after receipt of such notice.

(b)         The loss or departure of PRINCIPAL
INVESTIGATOR, and a mutually acceptable replacement cannot be found.

(c)          Performance of any part of this
Agreement by a party is prevented or delayed by reason of Force Majeure and
cannot be overcome by reasonable diligence to the satisfaction of either party.

(d)         The other party ceases,
discontinues or indefinitely suspends its business activities related to the
services to be provided under this Agreement, or the other party voluntarily or
involuntarily files for bankruptcy.

(e)          The party has given ninety (90)
days written notice to the other party.

12.2                           The party requesting termination will provide the other party with written
notice specifying both the reason and the effective date of termination.  Upon the giving of such notice of termination
by either party, the UNIVERSITY will use its reasonable best efforts to limit
or terminate any outstanding commitments.

12.3                           Upon termination, UNIVERSITY shall deliver to COMPANY in the state they
exist as of the date of termination of all work product, and Confidential
Information belonging to COMPANY. 
COMPANY shall within thirty (30) days after termination pay UNIVERSITY
all payments due as of the effective date of termination.

13.                               NOTICES

13.1                           All notices or communications given hereunder shall be in writing and shall
be delivered by hand, or by overnight courier, by facsimile with confirmation
by mail, with all delivery charges prepaid and addressed to the parties as
follows:

 

	
  TO COMPANY:

  	
   

  	
  Advanced Cell Technology, Inc.

  
	
   

  	
   

  	
  1201 Bay Harbor
  Parkway

  
	
   

  	
   

  	
  Alameda, CA
  94052

  
	
   

  	
   

  	
   

  
	
  TO UNIVERSITY:

  	
   

  	
  Director, Technology &
  Research Collaborations

  
	
   

  	
   

  	
  Oregon Health & Science University, AD120

  
	
   

  	
   

  	
  2525 SW First Avenue, Suite 120

  
	
   

  	
   

  	
  Portland, OR 97201-4753

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  with copy

  
	
   

  	
   

  	
   

  
	
  TO PRINCIPAL INVESTIGATOR:

  	
   

  	
  Raymond Lund

  

14.                               DISPUTE RESOLUTION AND GOVERNING LAW

14.1                           The Parties agree to attempt to settle amicably any controversy or claim
arising under this Agreement or a breach of this Agreement. Thereafter, both
parties agree that all disputes between them arising out of or relating to this
Agreement, will be submitted to non-binding mediation unless the parties
mutually agree otherwise.  All parties
agree to exercise their best effort in good faith to resolve all disputes in
mediation.

14.2                           This Agreement will be governed by and construed in accordance with the
laws of the State of Oregon without reference to its choice of law provisions,
the International Convention on the Sale of Goods or any other international
treaty.  Any claim, action or suit between
OHSU and COMPANY that arises out of or relates to performance of this Agreement
will be brought and conducted solely and exclusively within the Circuit Court
for Multnomah County, Oregon.  However,
if any such claim, action or suit may be brought only in a federal forum, it
will be brought and conducted solely and exclusively within the United States
District Court of Oregon.

15.                               CHANGES AND AMENDMENTS

15.1                           THIS AGREEMENT CONSTITUTES THE ENTIRE AGREEMENT BETWEEN THE PARTIES. THERE
ARE NO UNDERSTANDINGS, AGREEMENTS, OR REPRESENTATIONS, ORAL OR WRITTEN, NOT
SPECIFIED HEREIN REGARDING THIS AGREEMENT. 
NO AMENDMENT, CONSENT OR WAIVER OF TERMS OF THIS AGREEMENT SHALL BIND
EITHER PARTY UNLESS IN WRITING AND SIGNED BY ALL PARTIES.  ANY SUCH AMENDMENT, CONSENT, OR WAIVER SHALL
BE EFFECTIVE ONLY IN THE SPECIFIC INSTANCE AND FOR THE SPECIFIC PURPOSE
GIVEN.  COMPANY, BY THE SIGNATURE BELOW
OF ITS AUTHORIZED REPRESENTATIVE, ACKNOWLEDGES HAVING READ AND UNDERSTOOD THE
AGREEMENT AND COMPANY AGREES TO BE BOUND BY ITS TERMS AND CONDITIONS.

 

In Witness Whereof, the parties hereto have caused this
Agreement to be executed as of the date set forth herein by their duly
authorized representatives.

OREGON HEALTH & SCIENCE UNIVERSITY           ADVANCED CELL TECHNOLOGY, INC.

	
  By:

  	
   

  	
  /s/ ARUNDEEP PRADHAN

  	
  Feb. 28, 2007

  	
  By:

  	
  /s/ WILLIAM M. CALDWELL, IV

  	
  2/1/07

  
	
  Arundeep Pradhan, Director

  	
  Date

  	
  William Caldwell, IV

  	
  Date

  
	
  Technology and Research
  Collaborations

  	
   

  	
  Chairman and CEO

  	
   

  

 

	
  Acknowledged By: 

  	
   

  	
  /s/ Dr. RAYMOND LUND

  	
   

  	
  2/27/07

  	
   

  	
   

  
	
   

  	
   

  	
  Dr. Raymond Lund

  	
   

  	
  Date

  	
   

  	
   

  
	
   

  	
   

  	
  Principal Investigator

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]